Cell therapy weekly: groundbreaking results reported in cell therapy trial for multiple sclerosis

This week: highly positive results have been reported from a Phase II clinical trial assessing an autologous cell therapy for progressive multiple sclerosis, the US FDA has halted a Phase I/II dose-escalation trial evaluating BPX-601 CAR-T cells following reports of a patient death, a new ‘intermediate’ embryonic stem cell type has been developed, and an exclusive worldwide licence agreement has been announced for next-generation CAR-T therapies for the treatment of solid tumors. The news highlights: Groundbreaking results reported in cell therapy trial for multiple sclerosis US FDA halts clinical trial of BPX-601 CAR-T cells following patient death Researchers develop a...